Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

Our data shows VIZZ (aceclidine 1.44%) received FDA approval in July 2025, positioning the once-daily, preservative-free ...

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz ...

Vizz, a new FDA-approved eye drop, offers adults with age related near vision loss (presbyopia) a daily, non-surgical ...

The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic ...

The Food and Drug Administration has approved Vizz (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in ...

Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

Minghui Pharmaceutical Ltd. announced it is raising $131 million in a pre-IPO financing round Aug. 7. The funds will be used to advance its cancer and inflammatory disease pipeline, which include a PD ...